Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001418398 | SCV001620624 | likely benign | not provided | 2024-04-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002456676 | SCV002614670 | uncertain significance | Nephrolithiasis/nephrocalcinosis | 2024-09-03 | criteria provided, single submitter | clinical testing | The c.343G>A (p.A115T) alteration is located in exon 4 (coding exon 4) of the GRHPR gene. This alteration results from a G to A substitution at nucleotide position 343, causing the alanine (A) at amino acid position 115 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005040277 | SCV005681926 | uncertain significance | Primary hyperoxaluria, type II | 2024-02-13 | criteria provided, single submitter | clinical testing |